Zymeworks Inc. (ZYME) financials: revenue, earnings and cash flow
Fiscal 2020–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Zymeworks’s revenue went from $39M in fiscal 2020 to $106M in fiscal 2025, growth of about 22.2% a year.
Net income in fiscal 2025 was -$81M, a net margin of -76.6%; the best year in this period was 2022 with $124M.
Over the twelve months to September 30, 2026, revenue was $266M and net income $43M.
Free cash flow was -$35M in fiscal 2025 and positive in 1 of the 6 years shown.
The diluted share count rose 50% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $266M | $106M | $76M | $76M | $412M | $27M | $39M |
| Gross profit | — | — | — | — | — | — | — |
| Operating income | $44M | -$93M | -$137M | -$138M | $131M | -$216M | -$187M |
| Net income | $43M | -$81M | -$123M | -$119M | $124M | -$212M | -$181M |
| EPS (diluted) | $0.52 | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 | $-3.58 |
| R&D | $129M | $137M | $135M | $144M | $209M | $200M | $171M |
| Revenue growth | — | +38.9% | +0.4% | −81.6% | +1446.0% | −31.5% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$112M | -$33M | -$110M | -$118M | $144M | -$192M | -$151M |
| Capital spending | -$870000 | -$2M | -$2M | -$2M | -$8M | -$12M | -$4M |
| Free cash flow | -$113M | -$35M | -$112M | -$121M | $136M | -$205M | -$156M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $166M | $42M | $30M | $0 | $0 | — | — |
| Stock-based pay | $50M | $28M | $18M | $8M | $4M | $11M | $29M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash | — | $41M | $66M | $374M | $492M | $253M | $242M |
| Debt | — | $18M | $18M | $27M | $28M | $32M | — |
| Equity | — | $269M | $339M | $465M | $493M | $249M | $410M |
| Total assets | — | $347M | $463M | $581M | $649M | $389M | — |
| Shares (diluted) | 76M | 75M | 76M | 69M | 65M | 52M | 50M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | 16.6% | -87.3% | -179.7% | -181.6% | 31.6% | -808.2% | -481.3% |
| Net margin | 16.3% | -76.6% | -160.8% | -156.1% | 30.1% | -794.0% | -463.5% |
| FCF margin | -42.4% | -32.6% | -146.8% | -158.9% | 33.0% | -767.8% | -399.8% |
| ROIC | — | -25.5% | -30.3% | -28.0% | 23.0% | -76.5% | -36.1% |
| ROE | — | -30.2% | -36.2% | -25.5% | 25.2% | -85.0% | -44.0% |
Frequently asked questions
What is Zymeworks’s annual revenue?
$106M in fiscal 2025 and $266M over the twelve months to September 30, 2026.
How much profit does Zymeworks make?
Net income was -$81M in fiscal 2025 (net margin -76.6%).
Is Zymeworks’s revenue growing?
Yes: revenue rose 38.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.